155 related articles for article (PubMed ID: 36797234)
1. CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
Ilyas R; McCullough K; Badar T; Patnaik MM; Alkhateeb H; Mangaonkar A; Pardanani A; Tefferi A; Gangat N
Blood Cancer J; 2023 Feb; 13(1):26. PubMed ID: 36797234
[No Abstract] [Full Text] [Related]
2. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms.
Mwirigi A; Galli S; Keohane C; Raj K; Radia DH; Harrison CN; McLornan DP
Br J Haematol; 2014 Dec; 167(5):714-6. PubMed ID: 25048366
[No Abstract] [Full Text] [Related]
4. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Systchenko T; Chomel JC; Gallego-Hernanz P; Moya N; Desmier D; Maillard N; Bobin A; Vonfeld M; Gardeney H; Cayssials E E; Torregrosa J
Br J Haematol; 2023 Jul; 202(2):284-288. PubMed ID: 37183377
[TBL] [Abstract][Full Text] [Related]
5. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
6. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients.
Gangat N; Morsia E; Foran JM; Palmer JM; Elliott MA; Tefferi A
Br J Haematol; 2020 Dec; 191(5):e120-e124. PubMed ID: 32945528
[No Abstract] [Full Text] [Related]
7. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
8. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.
Abdelmagid MG; Al-Kali A; Begna KH; Hogan WJ; Litzow MR; Fleti F; Mangaonkar AA; Patnaik MS; Elliott MA; Alkhateeb H; Shi M; Howard MT; Reichard KK; Ketterling RP; Shah M; Pardanani A; Gangat N; Tefferi A
Haematologica; 2023 Sep; 108(9):2542-2545. PubMed ID: 36794509
[No Abstract] [Full Text] [Related]
9. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
10. SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
Patel AA; Odenike O
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):303-309. PubMed ID: 36907766
[TBL] [Abstract][Full Text] [Related]
11. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
Odenike O
Blood; 2018 Nov; 132(22):2339-2350. PubMed ID: 30333119
[TBL] [Abstract][Full Text] [Related]
12. Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene.
Mayeur-Rousse C; Sorel N; Voldoire M; Canioni D; Brizard F; Randriamalala E; Turhan AG; Chomel JC
Leuk Res; 2012 Mar; 36(3):377-81. PubMed ID: 22030335
[No Abstract] [Full Text] [Related]
13. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
[TBL] [Abstract][Full Text] [Related]
14. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
[TBL] [Abstract][Full Text] [Related]
15. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
16. What are the molecular mechanisms driving the switch from MPNs to leukemia?
Wang X; Hoffman R
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
[TBL] [Abstract][Full Text] [Related]
17. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
18. Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.
Tefferi A; Alkhateeb H; Gangat N
Blood Cancer J; 2023 Jul; 13(1):108. PubMed ID: 37460550
[TBL] [Abstract][Full Text] [Related]
19. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms.
Rampal RK; Mascarenhas JO; Kosiorek HE; Price L; Berenzon D; Hexner E; Abboud CN; Kremyanskaya M; Weinberg RS; Salama ME; Menghrajani K; Najfeld V; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Goldberg JD; Hoffman R
Blood Adv; 2018 Dec; 2(24):3572-3580. PubMed ID: 30563881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
